By Counterforce Health Team in Elelyso (taliglucerase alfa) —

How to Get Elelyso (Taliglucerase Alfa) Covered by Humana in New York: Forms, Appeals, and Support Resources

Quick Answer: Getting Elelyso (Taliglucerase Alfa) Covered by Humana in New York

Elelyso requires prior authorization through Humana's specialty pharmacy network (CenterWell). Your doctor submits the PA request via Humana's provider portal or fax to 1-888-447-XXXX (verify with source linked below). Standard approval takes up to 14 days; expedited review available for urgent cases (72 hours). If denied, you have 65 days to file an internal appeal, followed by independent review if needed. Medicare members follow federal appeals process; commercial plan members may access New York's external appeal system through the Department of Financial Services.

First step today: Have your prescriber check Humana's prior authorization requirements and begin gathering clinical documentation for Type 1 Gaucher disease diagnosis and dosing justification.

Table of Contents

  1. Verify Your Plan and Coverage Requirements
  2. Prior Authorization Forms and Requirements
  3. Submission Portals and Methods
  4. Specialty Pharmacy Enrollment
  5. Appeals Process in New York
  6. Support Resources and Contact Numbers
  7. Cost Assistance Programs
  8. Common Denial Reasons and Solutions
  9. When to Contact New York Regulators

Verify Your Plan and Coverage Requirements

Before starting the approval process, confirm your specific Humana plan type and Elelyso's coverage status:

Coverage at a Glance

Requirement Details Where to Find It
Prior Authorization Required for all Humana plans Humana PA Lists
Formulary Status Added to coverage effective April 16, 2025 Humana Medical Coverage Policies
Specialty Pharmacy CenterWell Specialty Pharmacy required CenterWell Information
Age Requirement FDA approved for patients ≥4 years FDA Access Data
Indication Type 1 Gaucher disease enzyme replacement therapy FDA Prescribing Information
Note: Elelyso (taliglucerase alfa) carries HCPCS code J1743 for professionally administered infusions.

Prior Authorization Forms and Requirements

Required Clinical Documentation

Your healthcare provider must submit comprehensive documentation supporting medical necessity:

Essential Elements:

  • Confirmed Type 1 Gaucher disease diagnosis (enzyme activity testing or genetic confirmation)
  • Patient age verification (≥4 years per FDA labeling)
  • Dosing rationale (typical starting dose: 60 units/kg every 2 weeks IV)
  • Prior treatment history and outcomes
  • Contraindications to alternative therapies if applicable
  • Treatment goals and monitoring plan

Medicare Part D Coverage Determination Forms

For Humana Medicare members, use the Medicare Part D Coverage Determination Form available in English and Spanish.

Key sections to complete:

  • Section 1: Patient and prescriber information
  • Section 2: Drug information (include NDC, strength, quantity)
  • Section 3: Medical necessity justification
  • Section 4: Supporting clinical documentation

Submission Portals and Methods

Primary Submission Options

1. Availity Provider Portal (Preferred Method)

  • Access at Availity.com
  • Real-time PA submission and status tracking
  • Upload supporting clinical documentation
  • Fastest processing time

2. Fax Submission

  • Medicare Part D requests: 877-486-2621
  • Professionally administered drugs: 1-888-447-XXXX (verify current number with Humana provider resources)

3. Phone Support

  • Provider line: 800-555-CLIN (2546), Mon-Fri 8 a.m.–8 p.m. local time
  • Payment Integrity support: 800-438-7885, Mon-Fri 8 a.m.–8 p.m. ET

Step-by-Step: Fastest Path to Approval

  1. Gather Documentation (Patient/Clinic): Collect diagnosis confirmation, prior therapy records, current labs
  2. Submit PA Request (Prescriber): Use Availity portal with complete clinical justification
  3. Track Status (Clinic): Monitor through portal; follow up if additional information requested
  4. Receive Determination (Patient): Written notice within 14 days (standard) or 72 hours (expedited)
  5. Coordinate Specialty Pharmacy (Patient/Clinic): Upon approval, CenterWell contacts for dispensing
  6. Schedule Infusion (Patient): Arrange administration at approved facility or home health
  7. Submit Claims (Provider): Include authorization number on claims (CMS-1500 Box 23, UB-04 Box 64)

Specialty Pharmacy Enrollment

Elelyso must be dispensed through Humana's specialty pharmacy network, primarily CenterWell Specialty Pharmacy.

Enrollment Process

After PA Approval:

  1. CenterWell contacts patient within 3-5 business days
  2. Benefits verification and copay calculation
  3. Prescription processing and cold-chain shipping coordination
  4. Infusion site coordination (home health or facility-based)
  5. Ongoing adherence monitoring and clinical support

Patient Responsibilities:

  • Provide updated insurance information
  • Confirm preferred infusion location
  • Schedule regular appointments for administration
  • Report any side effects or concerns to care team
Tip: Contact CenterWell directly at the number provided in your approval letter to expedite enrollment if you don't hear from them within one week.

Appeals Process in New York

Medicare Plans (Humana Medicare Advantage/Part D)

Medicare appeals follow a federal process with specific timelines:

Level 1: Plan Reconsideration

  • Timeline: File within 65 days of denial notice
  • Decision: 7 calendar days (standard) or 72 hours (expedited)
  • Method: Humana appeals form or call 800-867-6601

Level 2: Independent Review

  • Automatic: If Level 1 denied
  • Timeline: 7 days (standard) or 72 hours (expedited)
  • Reviewer: Independent Review Organization (IRO)

Levels 3-6: Administrative Law Judge, Medicare Appeals Council, Federal Court (if amount ≥$2,000)

Commercial Plans

New York residents with Humana commercial plans may access the state's external appeal system after exhausting internal appeals.

New York External Appeals:

  • File within 4 months of final adverse determination
  • $25 filing fee (waived for financial hardship)
  • Decision binding on insurer
  • 72-hour expedited review for urgent drug needs

Contact: New York Department of Financial Services

Support Resources and Contact Numbers

Humana Member Services

  • General: 800-457-4708
  • Medicare: 800-833-2364
  • Pharmacy: 800-379-0092
  • Appeals: 800-867-6601

Provider Support

  • Clinical: 800-555-CLIN (2546)
  • Prior Authorization: Available through Availity portal
  • CenterWell Specialty: Contact via provider portal

New York Consumer Assistance

  • Community Health Advocates: 888-614-5400 (free insurance counseling)
  • NY Department of Financial Services: Consumer assistance for insurance complaints
  • SHIP (State Health Insurance Assistance Program): Free Medicare counseling

Cost Assistance Programs

Pfizer Patient Support Programs

Pfizer Global Patient Services (GPS)

  • Phone: 1-855-353-5976
  • Benefits verification and PA support
  • Appeals assistance
  • Patient assistance program for uninsured/underinsured

Commercial Insurance Copay Support

  • Up to $15,000 annual benefit
  • $0 out-of-pocket for eligible patients
  • Excludes government insurance programs
  • Available at participating pharmacies only

Counterforce Health specializes in turning insurance denials into successful appeals for specialty medications like Elelyso. Their platform analyzes denial letters and plan policies to craft targeted, evidence-backed appeals that address specific payer requirements. By identifying the exact denial basis—whether PA criteria, step therapy, or medical necessity—and providing point-by-point rebuttals with appropriate clinical citations, they help patients and providers navigate complex approval processes more effectively.

Common Denial Reasons and Solutions

Denial Reason Required Documentation Action Steps
Unconfirmed diagnosis Enzyme activity results or genetic testing Submit beta-glucocerebrosidase deficiency confirmation
Age restriction Birth certificate or medical records Verify patient ≥4 years old per FDA labeling
Dosing outside guidelines Weight-based calculation Provide BSA/weight with 60 units/kg q2w justification
Step therapy required Prior treatment documentation Document trials/failures of plan-preferred ERTs
Not medically necessary Comprehensive clinical notes Submit disease progression, symptom severity, treatment goals

From Our Advocates

Based on our experience helping patients navigate Elelyso approvals, the most successful appeals include specific enzyme activity levels, documented organ involvement (spleen/liver enlargement, bone disease), and clear contraindications to alternative therapies. Plans respond well to structured medical necessity letters that reference FDA labeling and established treatment guidelines for Type 1 Gaucher disease.

When to Contact New York Regulators

Contact state regulators if you experience:

  • Unreasonable delays in PA processing
  • Improper denial of medically necessary treatment
  • Failure to follow established appeal procedures
  • Billing issues related to covered services

New York Department of Financial Services

For complex cases involving rare diseases like Gaucher disease, consider consulting with Counterforce Health, which specializes in evidence-based appeals for specialty medications and understands the specific documentation requirements that lead to successful approvals.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and procedures may change. Always verify current requirements with your insurance plan and consult your healthcare provider for medical decisions. For personalized assistance with insurance appeals, contact qualified patient advocacy services or legal counsel.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.